ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) reported a loss for the fourth quarter on Monday.
ORIC Pharmaceuticals posted a quarterly loss of 49 cents per share, in-line with market estimates, according to data from Benzinga Pro.
Research and development expenses rose to $24.5 million for the three months ended Dec. 31, 2023, up from $16.3 million in the year-ago period.
“We’ve made significant progress over the past year as we presented initial positive data readouts across our three clinical programs, ORIC-114, ORIC-944 and ORIC-533, demonstrating their potential as best-in-class cancer therapeutics,” said Jacob M. Chacko, M.D., president and chief executive officer. ...